SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of some unusual options trading on Thursday. Traders bought 8,459 put options on the stock. This is an increase of 208% compared to the average daily volume of 2,742 put options.

SELLAS Life Sciences Group Price Performance

SLS opened at $0.99 on Friday. The stock has a market cap of $69.60 million, a P/E ratio of -1.43 and a beta of 2.41. The stock’s 50 day simple moving average is $1.05 and its 200 day simple moving average is $1.16. SELLAS Life Sciences Group has a 1-year low of $0.50 and a 1-year high of $1.72.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Virtu Financial LLC lifted its holdings in SELLAS Life Sciences Group by 24.1% in the third quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock worth $99,000 after acquiring an additional 15,398 shares during the last quarter. Renaissance Technologies LLC bought a new stake in SELLAS Life Sciences Group during the second quarter worth approximately $39,000. State Street Corp grew its position in SELLAS Life Sciences Group by 30.2% in the third quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after buying an additional 40,500 shares during the last quarter. XTX Topco Ltd acquired a new position in SELLAS Life Sciences Group in the third quarter worth approximately $78,000. Finally, Geode Capital Management LLC grew its position in SELLAS Life Sciences Group by 17.1% in the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock worth $757,000 after buying an additional 88,183 shares during the last quarter. 17.38% of the stock is owned by hedge funds and other institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.